Nevadistinel

DB21632InvestigationalSmall molecule

Nevadistinel is a small molecule drug. The usage of the INN stem '-stinel' in the name indicates that Nevadistinel is a N-methyl-D-aspartate (NMDA) receptor co-agonist. Nevadistinel is under investigation in... Nevadistinel is under investigation in clinical trial NCT04148391 (NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)).

Mechanism: Pharmacologically active on NMDA receptor
Curator reviewed
Formula / weight: C₁₅H₁₈N₂O₃ · 274.32 g/mol (avg)
Code names: NYX-3054 · NYX-458

Resolves to

Compound

UNIIYYL9TO6TW2CAS2181816-92-0ChEMBLCHEMBL5314586

Structure

InChIKeyHMFZRGIXXDQHFG-HNNXBMFYSA-NSMILESCOC1=CC=C(CN2C[C@@]3(CCNC(=O)C3)C2=O)C=C1

What you can answer from here — as of September 19, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Nevadistinel, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account